Oxinas Partners Wealth Management LLC Cuts Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Oxinas Partners Wealth Management LLC decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 33.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,250 shares of the company’s stock after selling 5,650 shares during the quarter. Oxinas Partners Wealth Management LLC’s holdings in Recursion Pharmaceuticals were worth $74,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC boosted its holdings in Recursion Pharmaceuticals by 14.5% in the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after purchasing an additional 3,555,357 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after purchasing an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Recursion Pharmaceuticals by 2.2% in the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after purchasing an additional 349,554 shares during the last quarter. Kinnevik AB publ boosted its holdings in Recursion Pharmaceuticals by 14.4% in the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Recursion Pharmaceuticals by 12.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock worth $103,317,000 after purchasing an additional 1,159,023 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Insider Activity

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total value of $48,780.00. Following the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,353,265.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total value of $97,070.56. Following the sale, the director now directly owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares in the company, valued at approximately $4,353,265.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 201,682 shares of company stock worth $1,353,652 in the last three months. Company insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Down 0.7 %

Shares of RXRX stock opened at $6.67 on Wednesday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.17 and a beta of 0.80. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74. The company’s fifty day moving average price is $6.69 and its 200-day moving average price is $7.83. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.38) earnings per share. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Analyst Ratings Changes

RXRX has been the topic of several recent research reports. Jefferies Financial Group decreased their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Finally, KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.